0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

Stimulation of Megakaryocyte and Platelet Production by a Single Dose of Recombinant Human Thrombopoietin in Patients with Cancer

Saroj Vadhan-Raj, MD; Lesley J. Murray, PhD; Carlos Bueso-Ramos, MD; Shreyaskumar Patel, MD; Saraswati P. Reddy, MD; William K. Hoots, MD; Taren Johnston, RN; Nicholas E. Papadopolous, MD; Walter N. Hittelman, PhD; Dennis A. Johnston, PhD; Timothy A. Yang, BA; Virginia E. Paton, PharmD; Robert L. Cohen, MD; Susan D. Hellmann, MD; Robert S. Benjamin, MD; and Hal E. Broxmeyer, PhD
[+] Article and Author Information

From The University of Texas M.D. Anderson Cancer Center, Houston, Texas; SyStemix, Inc., San Francisco, California; Genentech, Inc., South San Francisco, California; and Indiana University School of Medicine, Indianapolis, Indiana. Acknowledgments: The authors thank Duane Bloedow, PhD, and Tauri Senn for their help in pharmacokinetics analysis; Yang Huh, MD, for immunophenotypic analysis; Karin Luens for ploidy analysis; Debbie Sayre and Nancy Hague for technical assistance; and Zenaida Silva for manuscript preparation. Grant Support: In part by R01 HL56416, R01 HL54037, and P01 HL53586 from the National Heart, Lung, and Blood Institute and by a research grant from Genentech, Inc. (South San Francisco, California). Requests for Reprints: Saroj Vadhan-Raj, MD, Department of Bioimmunotherapy, Box 002, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030. Current Author Addresses: Drs. Vadhan-Raj and Reddy and Ms. Johnston: Department of Bioimmunotherapy, Box 002, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030.


Copyright ©2004 by the American College of Physicians


Ann Intern Med. 1997;126(9):673-681. doi:10.7326/0003-4819-126-9-199705010-00001
Text Size: A A A

Background: Thrombocytopenia is frequently encountered in patients with cancer. It is associated with an increased risk for clinically important bleeding episodes, which increases the demand for platelet transfusion.

Objective: To assess hematopoietic response to and clinical tolerance of recombinant human thrombopoietin, a recently cloned novel cytokine.

Design: Phase I and II clinical cohort study.

Setting: The University of Texas M.D. Anderson Cancer Center, Houston, Texas.

Patients: 12 patients with sarcoma who had high risk for severe chemotherapy-induced thrombocytopenia.

Intervention: A single intravenous dose of thrombopoietin (0.3 to 2.4 µg/kg of body weight) 3 weeks before chemotherapy.

Measurements: Peripheral blood and bone marrow evaluation before and after thrombopoietin administration.

Results: A single dose of thrombopoietin was associated with an increase in platelet counts (mean increase from baseline, 61% to 213%; P = 0.002) in a dose-related manner. This increase began by day 4 in most patients and peaked on a median of day 12. This sustained response was associated with a prolonged serum thrombopoietin half life (20 to 30 hours). The platelets appeared morphologically normal and showed normal aggregation in response to various agonists. Platelet response was accompanied by a dose-related increase in bone marrow megakaryocytes (as much as 4-fold); the expansion of the bone marrow progenitors of myeloid, erythroid, multipotential, and megakaryocytic lineages; and the marked mobilization of progenitors (maximum, 5.7-fold to 10-fold) of multiple cell lineages in the peripheral blood. Treatment was well tolerated, and no serious adverse events occurred.

Conclusions: Thrombopoietin, administered as a single dose, is a potent stimulus for prolonged platelet production in humans. It merits further evaluation for the prevention and treatment of thrombocytopenia.

Figures

Grahic Jump Location
Figure 1.
Dose effect of thrombopoietin (TPO) on circulating platelet counts (left) and bone marrow megakaryocytes (right).

Percentage increases from baseline after various doses of thrombopoietin are shown. Data given are the mean + SE for all patients at each dose level.

Grahic Jump Location
Grahic Jump Location
Figure 2.
Kinetics of platelet response after a single dose (arrows) of thrombopoietin.

The data from each patient treated at four different dose levels are shown.

Grahic Jump Location
Grahic Jump Location
Figure 3.
Serum thrombopoietin (TPO) concentrations after intravenous bolus administration of thrombopoietin at different dose levels.

Data given are the mean + SE for three patients per dose level.

Grahic Jump Location
Grahic Jump Location
Figure 4.
Top.leftrightBottom.

Photomicrographs of a section of bone marrow from a patient before ( ) and after ( ) thrombopoietin treatment. Megakaryocytes are essentially normal in morphologic appearance; some are increased in size. Abundant cytoplasm and multilobulated nuclei are apparent. Masson trichrome-stained section of a bone marrow biopsy specimen. A markedly increased number of megakaryocytes is apparent, but collagen content after thrombopoietin treatment (right) is not increased compared with baseline (left).

Grahic Jump Location
Grahic Jump Location
Figure 5.
Bone marrow megakaryocyte DNA ploidy by flow cytometry before (white bars) and 7 days after (striped bars) thrombopoietin treatment. Top.nBottom.

Data given are the mean + SE for patients treated at all dose levels ( = 9). Data given are the mean + SE for four of five evaluable patients treated at the two highest dose levels. The fifth patient had a higher ploidy distribution at the start of treatment and is not included here.

Grahic Jump Location
Grahic Jump Location
Figure 6.
Frequency (left) and cycling status (right) of bone marrow myeloid (colony-forming unit-granulocyte-macrophage [CFU-GM]), erythroid (burst-forming unit-erythroid [BFU-E]), and multipotential (colony-forming unit-granulocyte, erythroid, macrophage, megakaryocyte [CFU-GEMM]) progenitors before and after thrombopoietin treatment.

Data given are the mean ± SE for all patients studied.

Grahic Jump Location
Grahic Jump Location
Figure 7.
Effect of thrombopoietin treatment on mobilization of myeloid (colony-forming unit-granulocyte-macrophage [CFU-GM]), erythroid (burst-forming unit-erythroid [BFU-E]), and myelo-erythroid (CFU-MIX) progenitors at 0.open bars

3 ( ), 0.6 (striped bars slanting up), 1.2 (black bars), and 2.4 (striped bars slanting down) µg/kg of body weight. Data shown represent the peak response (mean + SE), which was seen between days 3 and 7.

Grahic Jump Location

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Topic Collections
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)